{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'BIOCRYST', 'PHARMACEUTICALS, INC.', 'Protocol No. BCX7353-301', 'A PHASE 3, RANDOMIZED, DOUBLE-BLIND,', 'PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO', 'EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE', 'LEVELS OF BCX7353 AS AN ORAL TREATMENT FOR THE', 'PREVENTION OF ATTACKS IN SUBJECTS WITH', 'HEREDITARY ANGIOEDEMA', 'Version 6.0: 07 August 2020', 'BioCryst Pharmaceuticals, Inc.', '4505 Emperor Blvd., Suite 200', 'Durham, NC 27703', 'Phone: (919) 859-1302', 'Fax: (919) 851-1416', 'The information in this document contains proprietary and confidential information belonging to', 'BioCryst Pharmaceuticals, Inc. As a result, no part of this document should be copied, referred', 'to, released, published or otherwise disclosed in any manner or media without prior written', 'approval from BioCryst Pharmaceuticals, Inc.', 'CONFIDENTIAL', '1']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Substitution of Text after the Approval of BCX7353', 'Once BCX7353 (berotralstat) receives marketing authorization in Japan, this study will continue', 'as a post-marketing study until such time as BCX7353 is commercially available at each site.', 'The sponsor of the study will be changed from BioCryst Pharmaceuticals, Inc. (BioCryst) to the', 'marketing authorization holder in Japan, OrphanPacific, Inc. However, the clinical conduct of', 'the study will continue to be overseen by BioCryst. The study will be conducted in compliance', 'with Japan post-marketing regulations; only approved formulations and dosing regimens of', 'BCX7353 will be provided in the study. The text used in this protocol will be substituted as', 'follows:', 'Items', 'Substitution', 'Before Marketing Authorization', 'After Marketing Authorization', 'All text in the', 'Text describing investigational', 'Text describing post-marketing', 'protocol', 'clinical study', 'clinical study', '2']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Protocol Number:', 'BCX7353-301 (APeX-J)', 'Study Title:', 'A Phase 3, randomized, double-blind, placebo-controlled, parallel-group', 'study to evaluate the efficacy and safety of two dose levels of BCX7353 as', 'an oral treatment for the prevention of attacks in subjects with hereditary', 'angioedema', 'Investigational Product:', 'BCX7353', 'Indication Studied:', 'Hereditary angioedema', 'Sponsor:', 'Prior to BCX7353 marketing authorization in Japan:', 'BioCryst Pharmaceuticals, Inc. (BioCryst)', '4505 Emperor Boulevard, Suite 200', 'Durham, NC 27703, USA', 'After BCX7353 marketing authorization in Japan:', 'OrphanPacific, Inc.', '1-1-1 Shibaura, Minato-ku, Tokyo 105-0023, Japan', 'BioCryst will continue to oversee the clinical conduct of the', 'post-marketing study.', 'Japan Medical Monitor:', 'BioCryst Medical Monitoring team', 'Phone: +81-3-6811-2332', 'Email: mmj@biocryst.com', 'BioCryst Medical', 'Sylvia Dobo, MD', 'Monitor:', 'Phone (24 hours): +1 919-859-7905', 'Email: mmj@biocryst.com', 'BioCryst Clinical Study', 'Lacy Reese', 'Manager:', 'Office: + 1 919-226-5877', 'Email: lreese@biocryst.com', 'Compliance Statement:', 'This study will be conducted in accordance with the ethical principles that', 'have their origin in the Declaration of Helsinki and clinical research', 'guidelines established by the Code of Federal Regulations (Title 21, CFR', 'Parts 50, 56, and 312), International Council for Harmonisation guidelines,', 'and all locally applicable regulations. Essential study documents are', 'currently archived in accordance with applicable regulations.', 'Final Protocol Date(s):', 'Version 1.0: 19 July 2018', 'Version 2.0: 26 September 2018', 'Version 3.0: 11 October 2018 (matches Pharmaceuticals and Medical', 'Devices Agency [PMDA]-accepted Version 1.1 dated 01 October 2018)', 'Version 4.0: 15 October 2018', 'Version 5.0: 29 August 2019', 'Version 6.0: 07 Aug 2020', '3']\n\n###\n\n", "completion": "END"}